Organs-on-chips Market Analysis

Organs-on-chips Market Analysis

To get key market trends

  Download Free Sample

Based on type, the market size from the product segment is expected to generate a revenue of USD 944.7 million by 2032. The precise prediction of airborne nanoparticle absorption and accurate replication of the inflammatory response to microbial pathogens has stirred the widespread adoption of lung-on-chip models. The prevalence of pulmonary diseases, especially tuberculosis, has surged the demand for effective disease management, contributing to segment growth. According to the Center for Disease Control and Prevention (CDC), two billion people, accounting for one-fourth of the world’s population, get infected with tuberculosis (TB)annually.

Based on material, the organs-on-chips market from the polydimethylsiloxane (PDMS) segment is expected to record USD 646.9 million by 2032. Microfluidic organ-on-chip platform using PDMS has gained rapid popularity and widespread acceptance due to its compatibility with high-resolution microstructures and nanostructures through replica molding. PDMS is also recognized for its biocompatibility, optical transparency, and gas permeability, making it well-suited for biological applications.  
 

Based on model type, the single-organ model segment is anticipated to generate USD 881.5 million by 2032 attributed to their specificity and focused applications. The single-organ model maintains the ability to replace organ-level responses in a controlled environment, leading to widespread product adoption.
 

Based on application, the organs-on-chips market from the drug discovery segment will exhibit over 32% CAGR through 2032. The trials in novel drug discovery, characterized by rising R&D costs and low success rate in clinical trials is propelling the demand for advanced and precise predictive preclinical in-vitro models. 
 

Based on end-user, the organs-on-chips market value from the pharmaceutical and biotechnology companies segment reached USD 73.3 million in 2023. Several pharmaceutical and biotechnology companies are actively seeking innovative solutions to bridge the translational gap between preclinical and clinical drug development to reduce attrition rates. Substantial investments are helping them to prioritize R&D while focusing on personalized medicine, and consistently launching new products. Strong emphasis on enhancing preclinical testing efficiency will drive the segment growth. 
 

North America organs-on-chips market size was USD 44.9 million in 2023 and is anticipated to generate USD 533.9 million by 2032 attributed to the rising prevalence of chronic diseases. For instance, in June 2023, the FDA granted a partial option award to further propel the development of organ chips for radiation countermeasure research, evaluating efficacy and screening experimental compounds for Medical Countermeasures (MCM).  Furthermore, the growing investments by the public and private institutes, exemplified by the National Institutes of Health (NIH) funding for biotechnology will signify continuous regional growth.